TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors

Inclusion Criteria:

• Confirmed diagnosis of HCC by histology/ cytology or clinical criteria

• Sign informed consent

• When screening for age, the age should be ≥ 18 years old

• Eligible for TACE treatment

• ECOG physical condition score is 0 or 1

• No prior systemic therapy for HCC, especially immunotherapy

• According to the following mRECIST criteria, at least one measurable intrahepaticlesion is suitable for repeated evaluation

Exclusion Criteria:

• Have any history of kidney disease or nephrotic syndrome

• Evidence of extrahepatic spread (EHS)

• Cardiovascular diseases with clinical significance (such as activity), includingunstable angina, ≥ grade 2 congestive heart failure, and arrhythmia with poor drugtreatment control

• Any condition representing a contraindication to TACE as determined by theinvestigators

• Known genetic factors for bleeding or thrombosis; Any previous or current evidenceindicating a tendency for bleeding

• Individuals who have received immunotherapy (anti PD-1, anti PD-L1, or anti CTLA-4treatment)

• Previously received HAIC (hepatic artery infusion chemotherapy), TACE (hepaticartery chemoembolization), TAE (hepatic artery embolization), or TARE (hepaticartery radiation embolization)

• Previously received systemic anti-cancer treatment for HCC ,ICC or liver metastasis.